ライフサイエンスコーパス: total hip

1 spine; and -0.05, 95% CI -0.07 to -0.03 for total hip.

2 ut not less than -4.0 at the lumbar spine or total hip.

3 ent in BMD of 2.2% +/- 0.9% (P < .05) at the total hip.

4 ly associated with BMC in the whole body and total hip.

5 oral neck (0.022 +/- 0.006 g/cm2, P <0.001), total hip (0.029 +/- 0.006 g/cm2, P <0.001), and lumbar

6 2 versus 0.913 +/- 0.04 g/cm2; p = 0.01) and total hip (0.648 +/- 0.04 versus 0.811 +/- 0.04 g/cm2; p

7 e, +0.7 +/- 1.6; femoral neck, -0.1 +/- 1.1; total hip, 0.0 +/- 1.1).

8 e-by-group interaction: lumbar spine, 0.002; total hip, 0.03; whole body, 0.03).

9 h the tamoxifen group (lumbar spine, +2.77%; total hip, +0.74%).

10 ine, -0.2 +/- 1.6; femoral neck, -0.6 +/- 1; total hip, -0.6 +/- 1.1; matched, P < 0.01 at all sites)

11 e, -0.4 +/- 1.6; femoral neck, -0.7 +/- 1.1; total hip, -0.7 +/- 1.1).

12 femoral neck (2.39%; 95% CI: 3.61%, 1.17%), total hip (1.51%; 95% CI: 2.45%, 0.60%), and whole body

13 normal BMD (T score at the femoral neck and total hip, -1.00 or higher) or osteopenia (T score, -1.0

14 -1.70 +/- 0.25%; spine, -3.03 +/- 0.72%; and total hip, -1.87 +/- 0.60%.

15 ith mean (SD) increases of 5.9% (3.8) at the total hip, 10.4% (5.4) at the posteroanterior lumbar spi

16 0.5%) and F52 (lumbar spine, -6.2 +/- 0.9%; total hip, -10.3 +/- 1.4%; whole body, -3.2 +/- 0.6%).

17 = 0.001): NPNL (lumbar spine, -7.5 +/- 0.7%; total hip, -10.5 +/- 1.0%; whole body, -3.6 +/- 0.5%) an

18 r 5 years resulted in declines in BMD at the total hip (-2.4%; 95% confidence interval [CI], -2.9% to

19 ncreases of 2.6% for the femoral neck; 3.6%, total hip; 2.8%, spine; and 1.2%, total body.

20 4] vs -1.111% [-1.929 to -0.293]; p<0.0001), total hip (-3.856% [-4.449 to -3.264] vs -1.714% [-2.479

21 For the total hip, 3 year mean BMD change for women receiving an

22 -3.4] vs -1.2% [-1.7 to -0.7], p<0.0001) and total hip (-4.0% [-4.4 to -3.6] vs -1.8% [-2.1 to -1.4],

23 line to 5 years in lumbar spine (-6.08%) and total hip (-7.24%) compared with the tamoxifen group (lu

24 seline by 16.5% at the lumbar spine, 7.4% at total hip, 7.1% at femoral neck, and 2.3% at one-third r

25 seline by 21.7% at the lumbar spine, 9.2% at total hip, 9.0% at femoral neck, and 2.7% at the one-thi

26 For the total hip, a small 0.3% (-0.9 to 1.5) increase was noted

27 +/- 1.0% change from baseline; P < 0.05) and total hip aBMD (2.6% +/- 1.0% vs. -2.4% +/- 1.0% change;

28 rence 2.5%, 0.5 to 4.5, p=0.04), as did mean total hip aBMD (40 mug group, 6.1% [3.4] increase; 20 mu

29 t for age, body mass index, knee height, and total hip aBMD.

30 ine (1.5% change), and remained unchanged at total hip and femoral neck (-0.1% change).

31 reduced BMD at the lumbar spine (17 +/- 3%), total hip and femoral neck (24 +/- 3% and 20 +/- 4%, res

32 265 black women and 75 black men to predict total hip and femoral neck BMD or changes in BMD.

33 m supplementation reduced bone loss from the total hip and femoral neck in those who consumed <1.5 se

34 rge increases in bone mineral density at the total hip and femoral neck, as well as transitory increa

35 BMD of the lumbar spine, total hip and hip subregions, as measured by QCT, but on

36 luded changes in bone mineral density at the total hip and in markers of bone turnover, the time to c

37 BMD of the total hip and its subregions was measured using dual ene

38 Clinical improvement projects included total hip and knee joint replacement, hospitalist labora

39 made to physicians by five manufacturers of total hip and knee prostheses in 2007.

40 ompletely eliminated for patients undergoing total hip and knee replacement at the Richard L.

41 More than 70% of total hip and knee replacements are for osteoarthritis.

42 Center, Indianapolis, Indiana, revealed that total hip and knee replacements incurred $1.4 million in

43 y and completely eliminating non-VA care for total hip and knee replacements while increasing total j

44 Bone mineral density was measured at the total hip and lumbar spine using dual-energy x-ray absor

45 Total hip and spine areal BMD were determined with dual-

46 -related decline in bone density at both the total hip and the trochanter of 0.00044 g per square cen

47 to L4) and lateral lumbar (L2 to L4) spine, total hip (and subregions), and radius bone densities we

48 Total hip (and subregions), spine, and total-body BMDs w

49 ay absorptiometry, we compared lumbar spine, total hip, and femoral neck bone mineral density (BMD) i

50 HA-DLS, BMD at the femoral neck, trochanter, total hip, and lumbar spine (L2-L4) was associated with

51 nsity (BMD) at the femoral neck, trochanter, total hip, and lumbar spine (L2-L4) was measured by usin

52 steoporosis or osteopenia at the trochanter, total hip, and lumbar spine (L2-L4) were lower by 14% (O

53 are -2.6 at the lumbar spine and -1.9 at the total hip, and spine imaging shows several vertebral end

54 the trochanter, and 1.8+/-0.4 percent in the total hip, and the mean trabecular bone mineral density

55 crease in bone mineral density at the spine, total hip, and total body has been reported with raloxif

56 the mean percentage change from baseline in total hip areal BMD was 2.6% (95% CI 2.2 to 3.0) in the

57 ypass grafting and widened for 3 procedures, total hip arthroplasty (11.6 per 100 000 persons in male

58 repair surgery (fracture groups, n = 33) or total hip arthroplasty (nonfracture groups, n = 17).

59 ween such parameters and the 19-year risk of total hip arthroplasty (THA) for end-stage OA.

60 ace narrowing in the contralateral hip after total hip arthroplasty (THA) for osteoarthritis (OA) and

61 utcome and predictors of prognosis following total hip arthroplasty (THA) for osteoarthritis (OA).

62 low-up that included 556 patients undergoing total hip arthroplasty (THA) from December 2015 to Octob

63 Thirty-day readmission to hospital after total hip arthroplasty (THA) has significant direct cost

64 Offset restoration in total hip arthroplasty (THA) is associated with postoper

65 role of aspirin in thromboprophylaxis after total hip arthroplasty (THA) is controversial.

66 es on hospitals' SSI rates following primary total hip arthroplasty (THA) or total knee arthroplasty

67 A total of 108 men and women scheduled for total hip arthroplasty (THA) or total knee arthroplasty

68 ts about the preferred surgical approach for total hip arthroplasty (THA).

69 gained importance in assessment of pain with total hip arthroplasty (THA).

70 urce of dislocation and aseptic loosening in total hip arthroplasty (THA).

71 atient increased from 1.0 to 2.0 for primary total hip arthroplasty and 1.1 to 2.3 for revision (P <

72 groups (14.3% among the patients assigned to total hip arthroplasty and 13.1% among those assigned to

73 n occurred in 34 patients (4.7%) assigned to total hip arthroplasty and 17 patients (2.4%) assigned t

74 e Part A beneficiaries who underwent primary total hip arthroplasty and 348,596 who underwent revisio

75 atients (7.9%) who were randomly assigned to total hip arthroplasty and 60 of 723 patients (8.3%) who

76 risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital

77 occurred in 300 patients (41.8%) assigned to total hip arthroplasty and in 265 patients (36.7%) assig

78 in patients older than 10 years, 19 required total hip arthroplasty and none improved.

79 tients who were randomly assigned to undergo total hip arthroplasty and those who were assigned to un

80 emains uncertainty regarding the effect of a total hip arthroplasty as compared with hemiarthroplasty

81 capsule edema, and intramuscular edema after total hip arthroplasty at 1.5-T MRI with metal artifact

82 the results of both cemented and cementless total hip arthroplasty at mid- to long-term follow-up.

83 Modification codes for primary and revision total hip arthroplasty between 1991 and 2008.

84 Total hip arthroplasty continues to be an extremely succ

85 alloys have been used in dental implants and total hip arthroplasty due to their excellent biocompati

86 All subjects had undergone total hip arthroplasty for idiopathic arthritis, and the

87 nd any new radiographic finding of hip OA or total hip arthroplasty for OA (OR 1.71, 95% CI 1.16-2.52

88 lgesia benefit patients after total knee and total hip arthroplasty for pain management.

89 sed from 74.1 to 75.1 years and for revision total hip arthroplasty from 75.8 to 77.3 years (P < .001

90 ain management approach after total knee and total hip arthroplasty has increasingly become an altern

91 the mean age for patients undergoing primary total hip arthroplasty increased from 74.1 to 75.1 years

92 Total hip arthroplasty is a common surgical procedure bu

93 Total hip arthroplasty is a cost-effective surgical proc

94 management after total knee arthroplasty and total hip arthroplasty is pivotal, as it determines the

95 hat symptomatic venous thromboembolism after total hip arthroplasty most commonly develops after the

96 aced femoral neck fracture to undergo either total hip arthroplasty or hemiarthroplasty.

97 score, and function score, modestly favored total hip arthroplasty over hemiarthroplasty.

98 The proportion of primary total hip arthroplasty patients discharged home declined

99 A total of 45 351 total hip arthroplasty procedures were identified from 2

100 re assigned to undergo hemiarthroplasty, and total hip arthroplasty provided a clinically unimportant

101 Some allograft bone donated from primary total hip arthroplasty recipients must be discarded or t

102 (3%) with durable FICS undergoing definitive total hip arthroplasty surgery because of local tumor pr

103 y" to a low of 0.005 for "Procedure-Targeted Total Hip Arthroplasty Surgical Site Infection." General

104 2509 patients scheduled to undergo elective total hip arthroplasty were randomly assigned, stratifie

105 opic cholecystectomy, partial colectomy, and total hip arthroplasty were used.

106 pitalization (range: 61% for TURP to 88% for total hip arthroplasty), and are thus missed by the ProP

107 ay of 2 (1-2) days, 10 948 (37.4%) underwent total hip arthroplasty, 18 316 (62.6%) underwent total k

108 In patients who underwent total hip arthroplasty, a body-mass index of 25 or great

109 Among patients undergoing total hip arthroplasty, an anterior surgical approach co

110 ronary artery bypass grafting (CABG), 19% in Total Hip Arthroplasty, and 18% in Total Knee Arthroplas

111 nal aortic aneurysm (AAA) repair, colectomy, total hip arthroplasty, and pancreatectomy.

112 coronary artery bypass grafting, colectomy, total hip arthroplasty, hip fracture repair, and lumbar

113 For primary total hip arthroplasty, mean hospital LOS decreased from

114 For revision total hip arthroplasty, similar trends were observed in

115 sm repair, abdominal aortic aneurysm repair, total hip arthroplasty, total knee arthroplasty, and lun

116 lung resection, total knee arthroplasty, and total hip arthroplasty-between 2010 and 2014.

117 hroplasty and 348,596 who underwent revision total hip arthroplasty.

118 g symptomatic events, in patients undergoing total hip arthroplasty.

119 th clonidine was used in patients undergoing total hip arthroplasty.

120 fective pain management after total knee and total hip arthroplasty.

121 or thromboembolism within three months after total hip arthroplasty.

122 in 185 patients who had previously undergone total hip arthroplasty.

123 knee arthroplasty and 2298 of whom underwent total hip arthroplasty.

124 timodal pain management after total knee and total hip arthroplasty.

125 asured by QCT, but only the lumbar spine and total hip, as measured by DXA, were significantly associ

126 ne mineral densities at the femoral neck and total hip at 24 months and at all three sites at 36 mont

127 ineral density (BMD) in the lumbar spine and total hip between patients treated with exemestane and p

128 2.1%; P = .0109) and a numerical decrease in total hip BMD (-0.4%; P = .5988).

129 nant RFVOL was independently associated with Total Hip BMD (p < 0.001).

130 sion score was significantly correlated with total hip BMD (r=-0.33, P<0.0001), but not with lumbar s

131 For men, the correlation between total hip BMD and dairy calcium intake after adjustment

132 Conclusion: Treatment-related increases in total hip BMD are associated with reduced fracture risk

133 n a significant increase in lumbar spine and total hip BMD compared with A + P treatment (2.2% v -1.8

134 ability, women with a detectable decrease in total hip BMD compared with stable BMD had an absolute i

135 Similarly, total hip BMD declined by 0.8% at 6 months and 2.6% at 1

136 Women who had larger increases in total hip BMD during the first 12 months had a lower inc

137 3.2% of women with increases of > or =3% in total hip BMD experienced new vertebral fractures, where

138 incorporate bone mineral density (BMD), with total hip BMD in 10,418 WHI participants who had both de

139 0-g daily dose of prunes can prevent loss of total hip BMD in postmenopausal women after 6 mo, which

140 Total hip BMD increased 3.7% after 3 years of treatment

141 the lumbar spine BMD increased by 7.2%, and total hip BMD increased by 2.1% (P < 0.01 for both).

142 In the H stratum, lumbar spine and total hip BMD increased significantly (3.0%; P = .0006;

143 ients with serial bone density examinations, total hip BMD increased transiently in women with parath

144 nd soluble CD14 were associated with greater total hip BMD loss, whereas markers of CD4(+) T-cell sen

145 cumulative oral glucocorticoid dose, neither total hip BMD nor lumbar spine BMD was significantly ass

146 total hip BMD, and 21% had either decreased total hip BMD or no change.

147 n kg/m(2)) >27] postmenopausal women, with a total hip BMD t score less than -2.0.

148 al fracture ranged from 56% among women with total hip BMD T score of -2.5 or less and a prevalent ve

149 ular volumetric BMD, cortical thickness, and total hip BMD those with stage 0-2 fibrosis.

150 cture in women with a detectable increase in total hip BMD was 1.3% (CI, 0.4% to 2.2%) and 2.6% (CI,

151 ian (interquartile range) percent decline in total hip BMD was greater in those with high- compared t

152 A group x time interaction for total hip BMD was observed in control compared with 50-g

153 For women, each 1-SD reduction in total hip BMD was similarly associated with an increased

154 At 48 weeks, the percentage of decline in total hip BMD was smaller in the vitamin D3 plus calcium

155 Lumbar spine and total hip BMD were assessed at baseline and after 1, 2,

156 al fracture (odds ratio per 1 SD decrease in total hip BMD, 1.78 [95% confidence interval, 1.58-2.00]

157 of participants had increases of > or =3% in total hip BMD, and 21% had either decreased total hip BM

158 n-group difference was observed in change in total hip BMD, in favour of FG (0.007 g/cm2 [95% CI 0.00

159 osumab (2.1% [3.8], p=0.0238) groups, as did total-hip BMD (combination, 4.9% [2.9]; teriparatide, 0.

160 ementation had a small to moderate effect on total-hip BMD (WMD: 3.3%; 95% CI: 1.5%, 5.1%) but no eff

161 otal-body (P < 0.045), spine (P = 0.03), and total-hip BMDs (P = 0.029).

162 y endpoints were changes in lumbar spine and total hip bone mineral densities (BMDs); secondary endpo

163 he primary endpoint was percentage change in total hip bone mineral density (BMD) from baseline to we

164 Lumbar spine and total hip bone mineral density (BMD) were assessed at ba

165 The primary outcome was total hip bone mineral density (BMD), with femoral neck

166 The primary outcome measure was total hip bone mineral density (BMD); secondary measures

167 mean percentage changes in lumbar spine and total hip bone mineral density at week 48, assessed by d

168 cessary for a treat-to-target approach, with total hip bone mineral density being the best specific t

169 the bone mineral density secondary outcomes, total hip bone mineral density increased more in the ter

170 Total hip bone mineral density loss was similarly greate

171 for 5 years or more, with a femoral neck or total hip bone mineral density T-score between -2.5 and

172 pecific effect of weight change on change in total hip bone mineral density was evaluated over 4 year

173 36-month differences in percentage change in total hip bone mineral density were 0.79 percentage poin

174 Adjustment for total-hip bone mineral density eliminated the elevated r

175 - 0.8% at the spine and 2.8% +/- 0.5% at the total hip (both P < .001).

176 BMD increased at the total hip by 2.0% and 1.2%, respectively.

177 density was measured at the lumbar spine and total hip by dual-energy X-ray absorptiometry.

178 BMD of the total hip decreased by 1.9% +/- 0.7% in men assigned to

179 ant increases in bone mineral density at the total hip, femoral neck, and distal third of the radius

180 Baseline total hip, femoral neck, and lumbar spine BMDs were 1.01

181 e mineral density (BMD) at the lumbar spine, total hip, femoral neck, and one-third radius.

182 s with fracture had lower aBMD at the spine, total hip, femoral neck, and the ultradistal radius, the

183 s in bone mineral density of the total body, total hip, femoral neck, and trabecular bone of the lumb

184 an areal BMD T score of -2.5 or lower at the total hip, femoral neck, or lumbar spine; and a history

185 Bone mass at total hip, femoral neck, spine (L2-4), and whole body (W

186 change of BMD at 2 years in lumbar spine and total hip for both groups.

187 n BMD at the lumbar spine, femoral neck, and total hip from the end of year 1 (mean change -5.1%, -9.

188 crease]), as did bone mineral density at the total hip (grams per square centimeter; 1.010 to 0.996 [

189 At 12 months, bone mineral density at the total hip had increased more in the teriparatide group.

190 conduct a genome-wide association study for total hip (Hip) and femoral neck (FN) bone mineral densi

191 istage meta-analysis for lumbar spine (LS)-, total hip (HIP)- and femoral neck (FN)-bone mineral dens

192 Patients who had total hip/knee replacement were enrolled.

193 95% confidence interval [CI], 3.5%-4.3%) and total hip (mean change, 1.7% vs -0.1%; between-group dif

194 ; TBS (n = 204); BMD femoral neck (n = 220), total hip (n = 221), lumbar spine (n = 207).

195 a loss of 0.8 percent with placebo), at the total hip of 1.9 to 3.6 percent (as compared with an inc

196 A-adjusted BMC at the whole-body, spine, and total hip of between 1% and 4%.

197 cture, or a T-score of less than -4.0 at the total hip or femoral neck were not eligible unless they

198 Patients with OA receiving total hip or knee arthroplasty were recruited and comple

199 res, colectomy or proctectomy, hysterectomy, total hip or knee arthroplasty, ventral hernia repair, a

200 cacy and tolerability in patients undergoing total hip or knee arthroplasty.

201 Patients with RA who undergo total hip or knee replacement are at increased risk of p

202 included all patients with RA who underwent total hip or knee replacement at the Mayo Clinic Rochest

203 hylaxis against venous thromboembolism after total hip or knee replacement is uncertain.

204 Patients undergoing total hip or knee replacement or colorectal resections h

205 d 92 patients undergoing primary or revision total hip or knee replacement.

206 ance of young age and risk of revision after total hip or knee replacement.

207 Candidates for total hip or total knee arthroplasty were reviewed in a

208 T score of -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of t

209 al density T score in the lumbosacral spine, total hip, or femoral neck.

210 e spine, and had a 1.2% +/- 0.5% loss at the total hip (P < .05).

211 whereas MeDS (0-9) was associated only with total hip (P = 0.01) and trochanter BMD (P = 0.007) in p

212 the decrease in bone mineral density in the total hip (P = 0.031), trochanter (P = 0.006), hip neck

213 bar spine (P<0.001), trochanter (P = 0.003), total hip (P=0.005), and trabecular bone of the lumbar s

214 mbar [P = .03], femoral neck [P < .001], and total hip [P = .002]).

215 ies, and included 44 of these series (13 212 total hip placements).

216 sing dual-energy x-ray absorptiometry at the total hip, posterior-anterior spine, and total body; blo

217 t three clinical centers, baseline levels of total hip, posterior-anterior spine, and total-body bone

218 Total hip prostheses and spinal hardware that terminated

219 ral lumbar spine (r = 0.52, p < or = 0.001), total hip (r = 0.39, p = 0.01), total radius (r = 0.39,

220 resection ($63117 vs $21325; P < .001), and total hip replacement ($41354 vs $19028; P < .001).

221 n age, 67.6 years) were randomly assigned to total hip replacement (53 patients) or resistance traini

222 07647), pulmonary resection (n = 91758), and total hip replacement (n = 307399) between 2009 and 2012

223 ABG) (218940 patients at 1056 hospitals), or total hip replacement (THR) (231774 patients at 1831 hos

224 Mortality and complication rates after total hip replacement (THR) are inversely associated wit

225 Nearly 100,000 people underwent total hip replacement (THR) in the United Kingdom in 201

226 Total hip replacement (THR) is extremely common.

227 Implant survival after conventional total hip replacement (THR) is often poor in younger pat

228 Total hip replacement (THR) is successful in treating hi

229 ompared with patients undergoing an elective total hip replacement (THR) operation.

230 es the risk for venous thromboembolism after total hip replacement (THR) or total knee replacement (T

231 nd-stage hip osteoarthritis (OA) who undergo total hip replacement (THR) preferentially require subse

232 hyte score, decrease in MJS of > or =0.5 mm, total hip replacement (THR), and increase in lower extre

233 e rates in patients with hip OA undergoing a total hip replacement (THR), as compared with disease-fr

234 rates varied widely for patients undergoing total hip replacement (THR), colectomy, and pancreaticod

235 s, the progression of the disease required a total hip replacement (THR).

236 nter tenderness, hip pain or tenderness, and total hip replacement (THR).

237 h) and predictive validity (association with total hip replacement [THR] and signs and symptoms a mea

238 en concordant for primary OA (ascertained by total hip replacement [THR] or total knee replacement),

239 identified 63 158 patients who had undergone total hip replacement and 54 276 who had total knee repl

240 Among patients who had total knee or total hip replacement and received 4 to 10 days of posto

241 ng 15-year survival of primary, conventional total hip replacement constructs in patients with osteoa

242 using bisphosphonate, it eventually leads to total hip replacement due to collapse of femoral head.

243 hs, 5 patients (9%) who had been assigned to total hip replacement had not undergone surgery, and 12

244 d rates of CABG, carotid endarterectomy, and total hip replacement in 158 hospital-referral regions (

245 fee-for-service Medicare patients undergoing total hip replacement in 2016 at hospital systems identi

246 imate the population requirement for primary total hip replacement in England.

247 dance on wisdom tooth extraction and primary total hip replacement in the UK National Health Service.

248 Total hip replacement is a common and highly effective o

249 Total hip replacement is a commonly performed orthopedic

250 Death within 90 days after total hip replacement is rare but might be avoidable dep

251 quiring revision surgery in patients who had total hip replacement or total knee replacement over the

252 Practice Research Datalink who had undergone total hip replacement or total knee replacement.

253 In the 1960s, total hip replacement revolutionised management of elder

254 The Readmission After Total Hip Replacement Risk Scale was developed to predic

255 cation models, such as the Readmission After Total Hip Replacement Risk Scale, can identify high-risk

256 ey were used to create the Readmission After Total Hip Replacement Risk Scale, which was applied to t

257 rom a registry of patients who had undergone total hip replacement surgery over an 8-year period at a

258 The requirement for total hip replacement surgery was estimated on the basis

259 ndergone a primary or revision total knee or total hip replacement surgery.

260 if another family member also had undergone total hip replacement surgery.

261 For total hip replacement there was no significant change in

262 nical characteristics of patients undergoing total hip replacement were abstracted.

263 ervices dictate that further developments in total hip replacement will be governed by their cost-eff

264 tent of variation in episode spending around total hip replacement within and across hospital systems

265 proportion of male patients ranged from 37% (total hip replacement) to 77% (abdominal aortic aneurysm

266 en concordant for primary OA (ascertained by total hip replacement), were genotyped for 36 microsatel

267 For total hip replacement, 10-year implant survival rate was

268 als performing coronary artery bypass graft, total hip replacement, abdominal aortic aneurysm repair,

269 replacement, 214 patients who had undergone total hip replacement, and 520 controls from the UK.

270 y, other comorbidity, admission FIM ratings, total hip replacement, and time to followup.

271 suggests that the satisfaction of demand for total hip replacement, given agreed criteria for surgery

272 ity, comorbidity, admission FIM ratings, and total hip replacement, OA was associated with a longer r

273 endarterectomy, reduction of femur fracture, total hip replacement, total knee replacement, partial c

274 es who underwent future targeted procedures (total hip replacement, total knee replacements) or nonta

275 sk for minor bleeding in patients undergoing total hip replacement.

276 grafting (CABG), carotid endarterectomy, and total hip replacement.

277 ere concordant for hip OA, as ascertained by total hip replacement.

278 lulare, septic wrist, bacteremia, and septic total hip replacement.

279 s had a total knee replacement and 825 had a total hip replacement.

280 eral elective surgical treatments, including total hip replacement.

281 ssigned to resistance training had undergone total hip replacement.

282 that strongly associate with osteoarthritis total hip replacement: a missense variant, c.1141G>C (p.

283 ted with increased risk of readmission after total hip replacement: being older than 71 years (OR, 1.

284 knee replacements (TKRs), and 537 women with total hip replacements (THRs) from the Nottingham case-c

285 nce challenges the increasing trend for more total hip replacements and total knee replacements to be

286 Finland provided data for 92 series (215 676 total hip replacements).

287 performed a genome-wide association study of total hip replacements, based on variants identified thr

288 r the lateral spine, and 47% and 16% for the total hip, respectively.

289 one mineral density in both lumbar spine and total hip sites, with a significant positive effect of z

290 ts had significantly reduced BMD z-scores at total hip, spine, and WB.

291 apparent for spine fractures (P = 0.02) and total hip, spine, and wrist fractures (P = 0.02).

292 neral density screening revealed osteopenia, total hip T score of -1.8.

293 ed zoledronic acid when lumbar spine (LS) or total hip (TH) T score decreased to less than -2.0 or wh

294 6%, 0.97%, I(2): 0%; n = 5) but no effect on total hip (TH), femoral neck (FN), or total body BMD or

295 significantly higher BMD and z scores at the total hip than did nontanners.

296 D by dual-energy x-ray absorptiometry at the total hip through month 12 (mean of months 6 and 12), wh

297 Increases in BMD were also observed at the total hip, total body, femoral neck, and the predominant

298 A significant decrease in total hip trabecular vBMD was observed at 12 months in a

299 the mean annualized rate of bone loss at the total hip was -0.66% per year (95% confidence interval -

300 Loss of BMD at the femoral neck and total hip were also similar between treatment groups.

301 for the total-body radius, lumbar spine, and total hip were observed between subjects who received th